Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Selective inhibition of BET bromodomains

P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.2K citations · Full text

Bet Bromodomains, Genetics, Pathogenesis +3

Clonogenic assay of cells in vitro

Nicolaas A.P. Franken, Hans M. Rodermond, Jan Stap et al. · Nature Protocols · 2006 · 4K citations

Clonogenic Assay, Cell Culture, In Vitro Techniques +4

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text

Medicine, Immunology, Therapeutic Efficacy +7

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text